negative regulation of protein localization to actin cortical patch

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to actin cortical patch.


regulation of protein localization to chromatin

biolink:BiologicalProcess biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:Occurrent biolink:OntologyClass biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

Any process that modulates the frequency, rate or extent of protein localization to chromatin.


negative regulation of receptor clustering

Any process that stops, prevents or reduces the frequency, rate or extent of receptor clustering.


negative regulation of establishment of protein localization to telomere

Any process that stops, prevents or reduces the frequency, rate or extent of establishment of protein localization to telomere.


positive regulation of secretion of lysosomal enzymes

Any process that increases the rate, frequency or extent of secretion of lysosomal enzymes, the controlled release of lysosomal enzymes by a cell.


regulation of protein localization to cell cortex

Any process that modulates the frequency, rate or extent of protein localization to cell cortex.


regulation of axo-dendritic protein transport

Any process that modulates the frequency, rate or extent of axo-dendritic protein transport.


positive regulation of axo-dendritic protein transport

Any process that activates or increases the frequency, rate or extent of axo-dendritic protein transport.


regulation of protein targeting to vacuole involved in autophagy

Any process that modulates the frequency, rate or extent of protein targeting to vacuole involved in autophagy.


positive regulation of Wnt protein secretion

Any process that activates or increases the frequency, rate or extent of the controlled release of a Wnt protein from a cell.


positive regulation of protein localization to endoplasmic reticulum

Any process that activates or increases the frequency, rate or extent of protein localization to endoplasmic reticulum.


positive regulation of matrix metallopeptidase secretion

Any process that activates or increases the frequency, rate or extent of matrix metallopeptidase secretion.


regulation of protein localization to prospore membrane

Any process that modulates the frequency, rate or extent of protein localization to prospore membrane.


negative regulation of protein localization to basolateral plasma membrane

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to basolateral plasma membrane.


negative regulation of renin secretion into blood stream

Any process that stops, prevents or reduces the frequency, rate or extent of renin secretion into blood stream.


positive regulation of protein localization to membrane

Any process that activates or increases the frequency, rate or extent of protein localization to membrane.


regulation of BMP secretion

Any process that modulates the frequency, rate or extent of BMP secretion.


negative regulation of protein localization to ciliary membrane

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to ciliary membrane.


regulation of protein localization to lysosome

Any process that modulates the frequency, rate or extent of protein localization to lysosome.


positive regulation of protein targeting to vacuole involved in autophagy

Any process that activates or increases the frequency, rate or extent of protein targeting to vacuole involved in autophagy.


positive regulation of pancreatic amylase secretion by cholecystokinin signaling pathway

biolink:Pathway biolink:BiologicalProcess biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:OntologyClass biolink:Occurrent biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

A cholecystokinin signaling pathway that results in positive regulation of pancreatic amylase secretion.


negative regulation of protein localization to spindle pole body

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to spindle pole body.


regulation of protein localization to presynapse

Any process that modulates the frequency, rate or extent of protein localization to presynapse.


negative regulation of protein localization to cell-cell junction

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cell-cell junction.


negative regulation of protein localization to non-growing cell tip

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to a non-growing cell tip.


negative regulation of pancreatic amylase secretion

Any process that stops, prevents or reduces the frequency, rate or extent of pancreatic amylase secretion.


regulation of protein localization to phagocytic vesicle

Any process that modulates the frequency, rate or extent of protein localization to phagocytic vesicle.


regulation of protein localization to centrosome

Any process that modulates the frequency, rate or extent of protein localization to centrosome.


regulation of protein localization to cell tip

Any process that modulates the frequency, rate or extent of protein localization to cell tip.


negative regulation of protein localization to cell cortex

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cell cortex.


negative regulation of protein localization to nucleolus

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to nucleolus.


regulation of lipoprotein transport

Any process that controls lipoprotein transport.


regulation of protein localization to membrane

Any process that modulates the frequency, rate or extent of protein localization to membrane.


negative regulation of secretion of lysosomal enzymes

Any process that decreases the rate, frequency or extent of secretion of lysosomal enzymes, the controlled release of lysosomal enzymes by a cell.


negative regulation of matrix metallopeptidase secretion

Any process that stops, prevents or reduces the frequency, rate or extent of matrix metallopeptidase secretion.


positive regulation of protein localization to cell leading edge

Any process that activates or increases the frequency, rate or extent of protein localization to cell leading edge.


regulation of protein localization to kinetochore

Any process that modulates the frequency, rate or extent of protein localization to kinetochore.


negative regulation of protein localization to membrane

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to membrane.


negative regulation of protein localization to cilium

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cilium.


positive regulation of protein localization to endosome

Any process that activates or increases the frequency, rate or extent of protein localization to endosome.


regulation of protein localization to mitotic spindle pole body

Any process that modulates the frequency, rate or extent of protein localization to mitotic spindle pole body.


negative regulation of BMP secretion

Any process that stops, prevents or reduces the frequency, rate or extent of BMP secretion.


positive regulation of pancreatic amylase secretion

Any process that activates or increases the frequency, rate or extent of pancreatic amylase secretion.


regulation of protein localization to endoplasmic reticulum

Any process that modulates the frequency, rate or extent of protein localization to endoplasmic reticulum.


positive regulation of protein localization to ciliary membrane

Any process that activates or increases the frequency, rate or extent of protein localization to ciliary membrane.


regulation of protein localization to ciliary membrane

Any process that modulates the frequency, rate or extent of protein localization to ciliary membrane.


negative regulation of protein localization to centrosome

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to centrosome.


positive regulation of protein localization to lysosome

Any process that activates or increases the frequency, rate or extent of protein localization to lysosome.


negative regulation of protein localization to presynapse

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to presynapse.


negative regulation of skeletal muscle acetylcholine-gated channel clustering

Any process that stops, prevents or reduces the frequency, rate or extent of skeletal muscle acetylcholine-gated channel clustering.


negative regulation of prolactin secretion

Any process that stops, prevents or reduces the frequency, rate or extent of prolactin secretion.


regulation of protein localization to endosome

Any process that modulates the frequency, rate or extent of protein localization to endosome.


negative regulation of protein localization to cell cortex of cell tip

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to the cell cortex of the cell tip.


positive regulation of protein localization to cell-cell junction

Any process that activates or increases the frequency, rate or extent of protein localization to cell-cell junction.


positive regulation of protein localization to cell cortex

Any process that activates or increases the frequency, rate or extent of protein localization to cell cortex.


regulation of matrix metallopeptidase secretion

Any process that modulates the frequency, rate or extent of matrix metallopeptidase secretion.


regulation of protein localization to basolateral plasma membrane

Any process that modulates the frequency, rate or extent of protein localization to basolateral plasma membrane.


regulation of protein localization to non-growing cell tip

Any process that modulates the frequency, rate or extent of protein localization to a non-growing cell tip.


positive regulation of protein localization to prospore membrane

Any process that activates or increases the frequency, rate or extent of protein localization to prospore membrane.


negative regulation of protein localization to kinetochore

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to kinetochore.


positive regulation of lipoprotein transport

Any process that activates or increases the rate or extent of lipoprotein transport.


positive regulation of protein localization to cell tip

Any process that activates or increases the frequency, rate or extent of protein localization to cell tip.


regulation of pancreatic trypsinogen secretion

Any process that modulates the frequency, rate or extent of pancreatic trypsinogen secretion.


regulation of protein localization to cilium

Any process that modulates the frequency, rate or extent of protein localization to cilium.


regulation of glutamate receptor clustering

Any process that modulates the frequency, rate or extent of glutamate receptor clustering.


regulation of AMPA glutamate receptor clustering

Any process that modulates the frequency, rate or extent of AMPA glutamate receptor clustering.


regulation of pancreatic amylase secretion

Any process that modulates the frequency, rate or extent of pancreatic amylase secretion.


regulation of protein localization to adherens junction

Any process that modulates the frequency, rate or extent of protein localization to adherens junction. An adherens junction is a cell-cell junction composed of the epithelial cadherin-catenin complex at which the cytoplasmic face of the plasma membrane is attached to actin filaments.


regulation of protein localization to microtubule

Any process that modulates the frequency, rate or extent of protein localization to microtubule.


negative regulation of t-SNARE clustering

Any process that stops, prevents or reduces the frequency, rate or extent of t-SNARE clustering.


negative regulation of protein localization to endosome

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to endosome.


positive regulation of protein import into chloroplast stroma

Any process that activates or increases the frequency, rate or extent of protein import into chloroplast stroma.


negative regulation of protein localization to adherens junction

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to adherens junction. An adherens junction is a cell-cell junction composed of the epithelial cadherin-catenin complex at which the cytoplasmic face of the plasma membrane is attached to actin filaments.


regulation of protein localization to actin cortical patch

Any process that modulates the frequency, rate or extent of protein localization to actin cortical patch.


positive regulation of protein localization to cilium

Any process that activates or increases the frequency, rate or extent of protein localization to cilium.


positive regulation of protein localization to spindle pole body

Any process that activates or increases the frequency, rate or extent of protein localization to spindle pole body.


negative regulation of protein localization to meiotic spindle pole body

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to a meiotic spindle pole body.


positive regulation of asymmetric protein localization involved in cell fate determination

Any process that activates or increases the frequency, rate or extent of asymmetric protein localization involved in cell fate determination.


regulation of protein localization to meiotic spindle pole body

Any process that modulates the frequency, rate or extent of protein localization to a meiotic spindle pole body.


negative regulation of protein localization to Cajal body

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to Cajal body.


regulation of protein targeting to vacuolar membrane

Any process that modulates the frequency, rate or extent of protein targeting to vacuolar membrane.


negative regulation of asymmetric protein localization involved in cell fate determination

Any process that stops, prevents or reduces the frequency, rate or extent of asymmetric protein localization involved in cell fate determination.


regulation of MAPK export from nucleus

Any process that modulates the frequency, rate or extent of the directed movement of a MAP kinase from the nucleus to the cytoplasm.


regulation of neurotransmitter receptor localization to postsynaptic specialization membrane

Any process that modulates the frequency, rate or extent of neurotransmitter receptor localization to postsynaptic specialization membrane.


positive regulation of protein targeting to vacuolar membrane

Any process that activates or increases the frequency, rate or extent of protein targeting to vacuolar membrane.


negative regulation of protein localization to mitotic spindle pole body

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to mitotic spindle pole body.


regulation of neurotransmitter receptor transport, endosome to postsynaptic membrane

Any process that modulates the frequency, rate or extent of the directed movement of neurotransmitter receptor from the postsynaptic endosome to the postsynaptic membrane in transport vesicles.


positive regulation of protein export from nucleus during meiotic anaphase II

Any process that activates or increases the frequency, rate or extent of directed movement of proteins from the nucleus into the cytoplasm, during anaphase occurring as part of meiosis II.


negative regulation of protein localization to chromatin

Any process that stops, prevents, or reduces the frequency, rate or extent of protein localization to chromatin.


positive regulation of t-SNARE clustering

Any process that activates or increases the frequency, rate or extent of t-SNARE clustering.


regulation of protein localization by the Cvt pathway

Any process that modulates the frequency, rate or extent of protein localization by the Cvt pathway.


regulation of endosome to plasma membrane protein transport

Any process that modulates the frequency, rate or extent of endosome to plasma membrane protein transport.


positive regulation of chromosome passenger complex localization to kinetochore

Any process that activates or increases the frequency, rate or extent of a chromosome passenger complex localization to kinetochore.


regulation of protein localization to cell cortex of cell tip

Any process that modulates the frequency, rate or extent of protein localization to cell cortex of cell tip.


positive regulation of pancreatic trypsinogen secretion

Any process that activates or increases the frequency, rate or extent of pancreatic trypsinogen secretion.


positive regulation of protein localization to phagocytic vesicle

Any process that activates or increases the frequency, rate or extent of protein localization to phagocytic vesicle.


positive regulation of protein export from nucleus in response to glucose starvation

Any process that activates or increases the frequency, rate or extent of directed movement of proteins from the nucleus into the cytoplasm in response to deprivation of glucose.


positive regulation of protein localization to chromatin

Any process that activates or increases the frequency, rate or extent of protein localization to chromatin.


regulation of protein import into chloroplast stroma

Any process that modulates the frequency, rate or extent of protein import into chloroplast stroma.


negative regulation of protein localization to cell tip

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cell tip.


negative regulation of pancreatic trypsinogen secretion

Any process that stops, prevents or reduces the frequency, rate or extent of pancreatic trypsinogen secretion.


negative regulation of protein localization to endoplasmic reticulum

Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to endoplasmic reticulum.


qualitative or quantitative defects of protein involved in O-glycosylation of alpha-dystroglycan

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:ThingWithTaxon


qualitative or quantitative defects of alpha-dystroglycan


autosomal recessive limb-girdle muscular dystrophy type 2U

Any autosomal recessive limb-girdle muscular dystrophy in which the cause of the disease is a mutation in the ISPD gene.


qualitative or quantitative defects of FKRP


qualitative or quantitative defects of protein O-mannosyltransferase 2


muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7

Any muscular dystrophy-dystroglycanopathy, type A in which the cause of the disease is a mutation in the ISPD gene.


myopathy caused by variation in POMT2

Any myopathy in which the cause of the disease is a variation in the POMT2 gene.


limb-girdle muscular dystrophy due to POMK deficiency

Limb-girdle muscular dystrophy due to POMK deficiency is a form of limb-girdle muscular dystrophy presenting in infancy with muscle weakness and delayed motor development (eventually learning to walk at 18 months of age) followed by progressive proximal weakness, pseudohypertrophy of calf muscles, mild facial weakness, and borderline intelligence.


myopathy caused by variation in CRPPA

Any myopathy in which the cause of the disease is a variation in the CRPPA gene.


myopathy caused by variation in POMT1

Any myopathy in which the cause of the disease is a variation in the POMT1 gene.


muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A5


qualitative or quantitative defects of protein O-mannosyltransferase 1


autosomal recessive limb-girdle muscular dystrophy type 2K

Autosomal recessive limb-girdle muscular dystrophy type 2K (LGMD2K) is a form of limb-girdle muscular dystrophy characterized by the onset of slowly progressive proximal muscle weakness during childhood (with fatigue and difficulty running and climbing stairs) and developmental delay. Mild intellectual deficit and microcephaly, without any obvious structural brain abnormality, are found in all patients. Mild pseudohypertrophy and joint contractures of the ankles have also been reported.


autosomal recessive limb-girdle muscular dystrophy type 2I

A subtype of autosomal recessive limb-girdle muscular dystrophy that presents a highly variable age of onset and phenotypic spectrum typically characterized by slowly progressive proximal weakness of the pelvic and shoulder girdle musculature (predominantly affecting the lower limbs), frequently associated with waddling gait, scapular winging, calf and tongue hypertrophy, exercise-induced myalgia, and myoglobinuria and/or elevated creatine kinase serum levels. Abdominal muscle weakness, cardiomyopathy, respiratory muscle involvement and various brain abnormalities have also been reported.


autosomal recessive limb-girdle muscular dystrophy type 2N

Autosomal recessive limb-girdle muscular dystrophy type 2N (LGMD2N) is a form of limb-girdle muscular dystrophy characterized by proximal weakness (manifesting as slowness in running) presenting in infancy, along with calf hypertrophy, mild lordosis, scapular winging and normal intelligence or mild intellectual disability.


muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2

An autosomal recessive inherited congenital muscular dystrophy caused by mutations in the POMT2 gene. It is characterized by mental retardation and mild structural brain abnormalities resulting from defective glycosylation of alpha-dystroglycan.


muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1


left suprarenal vein

biolink:GrossAnatomicalStructure biolink:AnatomicalEntity biolink:OrganismalEntity biolink:BiologicalEntity biolink:NamedThing biolink:PhysicalEssence biolink:SubjectOfInvestigation biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

A vein that drains blood from the left adrenal gland into the left renal artery.


galanin-activated signaling pathway

The series of molecular signals generated as a consequence of the peptide neurotransmitter galanin binding to a cell surface receptor.


Broad Ligament Papillary Cystadenoma

A cystadenoma that arises from the broad ligament. It is characterized by the presence of small papillary projections in the inner surface of the cysts. It may be sporadic or associated with von Hippel-Lindau disease.


bile acid taurine conjugate

A bile acid conjugate resulting from the formal condensation of a bile acid with the amino group of taurine.


5beta-cholanic acids

Members of the class of cholanic acids based on a 5beta-cholane skeleton.


hydroxy-5beta-cholanic acid

Any member of the class of 5beta-cholanic acids carrying at least one hydroxy group at unspecified position.


bile acid conjugate

Any bile acid conjugated to a functional group that gives additional hydrophilicity or charge to the molecule. Molecules used for conjugation are: glycine, taurine (and other amino acids); sulfuric acid (for which the term ''sulfate'' may be used); glucuronic acid (for which the term ''glucuronate'' may be used); glucose and other uncharged sugars; and coenzyme A.


dihydroxy-5beta-cholanic acid

A hydroxy-5beta-cholanic acid carrying two hydroxy groups at unspecified positions.


bile acid

Any member of a group of hydroxy-5beta-cholanic acids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine. In mammals bile acids almost invariably have 5beta-configuration.


bile acids

Any member of a group of hydroxy steroids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine. In mammals bile acids almost invariably have 5beta-configuration, while in lower vertebrates, some bile acids, known as allo-bile acids, have 5alpha-configuration.


dihydroxycholanic acid

Any member of the class of cholanic acids carrying two hydroxy substituents at unspecified positions.


acyl-CoA N-acyltransferase activity

biolink:MolecularActivity biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:Occurrent biolink:OntologyClass biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

Catalysis of the transfer of an acyl group from acyl-CoA to a nitrogen atom on an acceptor molecule.


Cervical Warty Carcinoma

A human papillomavirus-related cervical squamous cell carcinoma characterized by the presence of a warty surface and koilocytotic atypia.


pseudohypoaldosteronism type 2D

Any pseudohypoaldosteronism type 2 in which the cause of the disease is a mutation in the KLHL3 gene.


temporomandibular joint disorder

Any condition affecting the anatomic and functional characteristics of the temporomandibular joint.


Craniomandibular Disorders

A disorder that affects the muscles of head and neck and temporomandibular joint.


osteofibrous dysplasia

A benign, usually self-limited fibro-osseous lesion of the bone that affects infants and children. It usually arises from the cortical bone of the anterior mid-shaft of the tibia. Patients usually present with swelling or painless bowing of the tibia. Progression to adamantinoma has been reported in some cases.


syringal lignin catabolic process

The chemical reactions and pathways resulting in the breakdown of syringal lignin.


negative regulation of toll-like receptor 9 signaling pathway

Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 9 signaling pathway.


epaxial region somite 24

The epaxial region of somite 24 derived body wall muscle. The epaxial region is dorsal to the horizontal myoseptum. Kimmel et al, 1995.


Stage IIIC Ovarian Cancer

Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal metastasis beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIIB Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIIB includes: T3b, N0, M0. T3b: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIB Ovarian Cancer AJCC v8

Stage IIB includes: T2b, N0, M0. T2b: Ovarian cancer with tumor extension to and/or implants on other pelvic tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Stage IIIA Ovarian Cancer AJCC v6 and v7

Stage IIIA includes: T3a, N0, M0.  T3a: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified

A sex cord-stromal tumor that arises from the ovary and lacks the morphologic features that belong to the categories of granulosa-stromal tumors, Sertoli-stromal tumors, or steroid cell tumors.


Recurrent Malignant Ovarian Brenner Tumor

The reemergence of malignant ovarian Brenner tumor after a period of remission.


Stage IC Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IC includes: (T1c, N0, M0).  T1c: Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


DICER1-Mutant Ovarian Sertoli-Leydig Cell Tumor

Ovarian Sertoli-Leydig cell tumor characterized by the presence of DICER1 gene mutation. It is associated with moderately and poorly differentiated histological features, presence of retiform or heterologous elements, and younger age.


FIGO Stage IIIA2 Ovarian Cancer

Ovarian cancer with microscopic, extrapelvic (above the brim) peritoneal involvement +/- positive retroperitoneal lymph nodes. (FIGO, 2014)


ovarian endometrioid stromal and related neoplasms

A category of rare neoplasms that arise from the ovary. It includes low grade endometrioid stromal sarcoma and undifferentiated sarcoma.


Ovarian Neuroendocrine Carcinoma

A small cell carcinoma, pulmonary-type or large cell neuroendocrine carcinoma arising from the ovary.


Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor with Microinvasion

A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic mucinous epithelial cells, atypia, and microinvasion of the ovarian stroma.


Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Borderline Ovarian Mixed Epithelial Tumor/Atypical Proliferative Ovarian Mixed Epithelial Tumor

A low grade, non-invasive mixed epithelial proliferative neoplasm that arises from the ovary. In most cases is composed of serous and endocervical-type mucinous cells.


Stage IV Ovarian Cancer AJCC v6 and v7

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Metastatic Ovarian Clear Cell Adenocarcinoma

Ovarian clear cell adenocarcinoma that has spread from its original site of growth to another anatomic site.


Stage IIB Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIB includes: T2b N0, M0. T2b: Extension and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


FIGO Stage IVA Ovarian Cancer

Ovarian cancer with pleural effusion with positive cytology. (FIGO, 2014)


Borderline Ovarian Mucinous Tumor

A low grade mucinous epithelial neoplasm arising from the ovary.  It is characterized by an atypical proliferation of mucinous-type epithelial cells without evidence of stromal invasion.  The mucinous epithelial cells may be of intestinal or endocervical type.


Recurrent Ovarian Transitional Cell Carcinoma

The reemergence of ovarian transitional cell carcinoma after a period of remission.


Stage IIIC Ovarian Cancer AJCC v8

Stage IIIC includes: T3c, N0/N1, M0. T3c: Ovarian cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Ovarian Mixed Cell Adenocarcinoma

An adenocarcinoma that arises from the ovary and is characterized by the presence of two or more adenocarcinoma components, most often endometrioid and clear cell.


Stage III Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2

Tumor involves one or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Ovarian Fibroma

A fibroma that arises from the ovary during childhood.


Locally Advanced Ovarian Carcinoma

Ovarian carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Childhood Ovarian Small Cell Carcinoma, Hypercalcemic Type

A rare ovarian small cell carcinoma, hypercalcemic type that occurs during childhood.


Recurrent Ovarian Undifferentiated Carcinoma

The reemergence of ovarian undifferentiated carcinoma after a period of remission.


Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2 Stage

A term that refers to the staging of childhood ovarian germ cell tumor according to the Toronto childhood cancer staging guidelines v2.


Ovarian Soft Tissue Neoplasm

A benign, intermediate, or malignant mesenchymal neoplasm of the ovary. Representative examples include leiomyoma, myxoma, and sarcoma.


ovarian stromal hyperthecosis

A non-neoplastic disorder that usually affects postmenopausal women. It is characterized by the leuteinization of ovarian stromal cells. The ovaries are bilaterally involved and enlarged. When it affects women in reproductive age, it causes virilization, high blood pressure, and increased insulin levels.


Metastatic Ovarian Carcinosarcoma

Ovarian carcinosarcoma that has spread from its original site of growth to another anatomic site.


Stage I Ovarian Germ Cell Tumor AJCC v6 and v7

Stage I includes: (T1, N0, M0). T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


DICER1/FOXL2-Wildtype Ovarian Sertoli-Leydig Cell Tumor

Ovarian Sertoli-Leydig cell tumor characterized by the absence of DICER1 and FOXL2 gene mutations. It is associated with well-differentiated histological features, absence of retiform or heterologous elements, and intermediate age.


malignant sex cord stromal tumor of ovary

Malignant sex cord stromal tumor (SCST) of ovary is a rare ovarian cancer arising from granulosa, theca, sertoli and leydig cells or stromal fibroblasts, occurring at any age and presenting with abdominal or pelvic mass, and characterized (with the exception of fibroma) by the production of sex steroids resulting in manifestations of hormone excess, with a relatively favorable prognosis.


Stage IIIB Ovarian Cancer AJCC v8

Stage IIIB includes: T3b, N0/N1, M0. T3b: Ovarian cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Stage II Borderline Ovarian Surface Epithelial-Stromal Tumor

Stage II includes: T2, N0, M0.  T2: Tumor involves one or both ovaries with pelvic extension and/or implants.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Ovarian Mucinous Carcinoid Tumor

A rare carcinoid tumor that arises from the ovary and is characterized by the presence of glands that are lined by cells that contain intracytoplasmic mucin or resemble goblet cells.  Pools of mucin, containing glands, may also be present.  It may have an aggressive clinical course and it can metastasize to other anatomic sites.


ovarian Sertoli-Leydig cell tumor

A benign or malignant sex cord-stromal tumor arising from the ovary. It is characterized by the presence of neoplastic Leydig cells. Signs and symptoms include hirsutism, menorrhagia and metrorrhagia. It may be associated with trisomy 8.


Well Differentiated Ovarian Steroid Cell Tumor

An ovarian steroid cell tumor not otherwise specified, and characterized by the absence of nuclear atypia, mitotic figures, necrosis, and hemorrhage.


Refractory Ovarian Clear Cell Adenocarcinoma

Ovarian clear cell adenocarcinoma that is resistant to treatment.


Ovarian Wolffian Tumor

An epithelial neoplasm of Wolffian (mesonephric) origin arising from the ovarian hilum. Most tumors behave in a benign fashion.


Ovarian Stromal-Leydig Cell Tumor

A rare, benign and well circumscribed stromal tumor of the ovary.  It is characterized by the presence of a fibrotic stroma with clusters of Leydig cells.  The Leydig cells contain crystals of Reinke.  Patients may present with virilization.


Stage IIA Ovarian Cancer AJCC V6 and v7

Stage IIA includes: T2a, N0, M0.  T2a: Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


non-gestational ovarian choriocarcinoma

A malignant germ cell tumor that arises from the ovary and is composed of cytotrophoblasts, syncytiotrophoblasts, and extravillous trophoblasts. The prognosis is less favorable than gestational choriocarcinoma.


Stage IB Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IB includes: (T1b, N0, M0). T1b: Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Recurrent Low Grade Ovarian Endometrioid Adenocarcinoma

The reemergence of low-grade ovarian endometrioid adenocarcinoma after a period of remission.


Borderline Ovarian Clear Cell Tumor/Atypical Proliferative Ovarian Clear Cell Tumor with Intraepithelial Carcinoma

A non-invasive clear cell adenofibromatous neoplasm that arises from the ovary. It is characterized by the presence of atypical neoplastic clear or hobnail epithelial cells and intraepithelial carcinoma.


FIGO Stage IIIA1(i) Ovarian Cancer

Ovarian cancer with positive retroperitoneal lymph nodes only. Metastasis equal or less than 10 mm. (FIGO, 2014)


malignant non-dysgerminomatous germ cell tumor of ovary

A malignant germ cell tumor other than dysgerminoma that arises from the ovary.


Malignant Ovarian Luteinized Thecoma

A thecoma of the ovary that contains lutein cells and may metastasize to other anatomic sites. It is usually characterized by nuclear atypia and mitotic activity.


ovarian angiosarcoma

A malignant vascular neoplasm arising from the ovary.


Stage II Ovarian Polyembryoma AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage I Borderline Ovarian Surface Epithelial-Stromal Tumor

Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Stage IIIA Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIIA includes: T3a, N0, M0. T3a: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Recurrent Ovarian Carcinosarcoma

The reemergence of ovarian carcinosarcoma after a period of remission.


Childhood Malignant Ovarian Neoplasm

A malignant neoplasm that affects the ovary and occurs during childhood.


Ovarian germ cell choriocarcinoma stage II


Recurrent BRCA- Associated Ovarian Carcinoma

The reemergence of BRCA-associated ovarian carcinoma after a period of remission.


ovarian endometriosis

A non-neoplastic disorder characterized by the growth of endometrial tissue in the ovaries. It results in the development of blood filled ovarian cysts (chocolate cysts), and creation of scars and adhesions.


Borderline Ovarian Serous Tumor/Atypical Proliferative Ovarian Serous Tumor

A non-invasive serous neoplasm that arises from the ovary and shows greater cellular proliferation and cytologic atypia as compared to benign ovarian serous tumors, but less as compared to low-grade ovarian serous carcinoma.


ovarian gynandroblastoma

A rare neoplasm arising from the ovary. Although it may occur at any age, it is more often seen in young females. Morphologically, it is characterized by a mixture of two cellular populations: well differentiated Sertoli cells and granulosa cells, with the latter constituting at least ten percent of the neoplasm. The vast majority of cases are stage I lesions at presentation and produce either estrogenic or androgenic manifestations. Although it may present as a massive ovarian tumor, it usually follows a benign clinical course. Very rare case reports of testicular lesions morphologically resembling gynandroblastomas are in fact variants of juvenile granulose cell tumor, or Sertoli cell tumor, or a combination of both.


Stage IIIB Ovarian Cancer AJCC v6 and v7

Stage IIIB includes: T3b, N0, M0.  T3b: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Refractory Extrarenal Rhabdoid Tumor of the Ovary

An extrarenal rhabdoid tumor of the ovary that is resistant to treatment.


FOXL2 c.402C>G (p.Cys134Trp)-Mutant Ovarian Sertoli-Leydig Cell Tumor

Ovarian Sertoli-Leydig cell tumor characterized by mutation at position 402 of the coding sequence of the FOXL2 gene where cytosine has been replaced by guanine. It is associated with moderately and poorly differentiated histological features and absence of retiform or heterologous elements. It is described in postmenopausal patients.


Refractory Ovarian Squamous Cell Carcinoma

Ovarian squamous cell carcinoma that is resistant to treatment.


Benign epithelial tumor of ovary

A neoplasm that arises from the surface epithelium of the ovary and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include serous cystadenoma, mucinous cystadenoma, clear cell adenofibroma, and benign Brenner tumor.


ovarian adenosarcoma

A biphasic neoplasm that arises from the ovary and is characterized by the presence of mullerian-type epithelial tissue in a mesenchymal sarcomatous stroma. The presence of a high grade sarcomatous component is associated with recurrences and metastases.


Stage IV Ovarian Polyembryoma AJCC v6 and v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Ovarian germ cell choriocarcinoma stage I

Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Ovarian Smooth Muscle Tumor of Uncertain Malignant Potential

A smooth muscle neoplasm that arises from the ovary and cannot be reliably diagnosed as benign or malignant, because of the presence of ambiguous morphologic findings.


Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor

A Sertoli-Leydig tumor of the ovary characterized by the presence of a sarcomatoid stroma which contains primitive gonadal stromal cells. It may behave in a malignant fashion and metastasize to other anatomic sites.


Malignant Ovarian Thecoma

A thecoma of the ovary which may metastasize to another anatomic site. It is usually characterized by nuclear atypia and mitotic activity. Malignant thecomas are rare.


Ovarian Mucinous Cystic Tumor Associated with Pseudomyxoma Peritonei

The presence of abundant mucoid or gelatinous, cellular or acellular material in the pelvis and abdominal cavity (pseudomyxoma peritonei) that is associated with the presence of an ovarian mucinous cystic tumor.  In the vast majority of cases, the presence of pseudomyxoma peritonei is the result of metastasis from a primary appendiceal or gastrointestinal tumor site, and the ovarian mucinous tumor is metastatic rather than primary.


Ovarian Cancer by AJCC v8 Stage

A term that refers to the staging of ovarian cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to ovarian carcinomas. Nonepithelial primary ovarian cancers may be staged using this classification but should be reported separately. (from AJCC 8th Ed.)


Ovarian Signet Ring Stromal Tumor

A rare, benign sex cord-stromal tumor that arises from the ovary. It is characterized by the presence of round cells with a single cytoplasmic vacuole and an eccentric nucleus resembling signet ring cells. Mucin stains are negative.


Stage I Ovarian Dysgerminoma AJCC v6 and v7

Stage I includes: (T1, N0, M0). T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Recurrent Ovarian Adenocarcinoma

The reemergence of ovarian adenocarcinoma after a period of remission.


Ovarian Seromucinous Cystadenoma

A non-metastasizing cystic mixed epithelial neoplasm that arises from the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous.


FIGO Grade 2 Ovarian Endometrioid Adenocarcinoma

Ovarian  endometrioid adenocarcinoma exhibiting 6-50% solid non-glandular, non-squamous growth.


Ovarian Smooth Muscle Neoplasm

A benign, intermediate, or malignant neoplasm that arises from the ovary and is composed of neoplastic cells with smooth muscle differentiation.


Ovarian Low Grade Endometrioid Stromal Sarcoma

A rare invasive mesenchymal tumor that arises from the ovary.  It is characterized by the absence of marked pleomorphism and nuclear atypia in the neoplastic mesenchymal cells.  It may have a favorable clinical outcome.


Ovarian Sertoli Cell Tumor with Lipid Storage

A Sertoli cell tumor that arises from the ovary and is characterized by the presence of cells that are distended by the presence of intracytoplasmic lipid.


pediatric ovarian germ cell tumor

A germ cell tumor that arises from the ovary and occurs in children.


Ovarian Mesonephric-Like Adenocarcinoma

An exceedingly rare adenocarcinoma that arises from the ovary and displays mesonephric differentiation. Some tumors are thought to derive from mesonephric duct (Wolffian duct) remnants. Others may have a Mullerian duct lineage.


Recurrent Malignant Ovarian Granulosa Cell Tumor

The reemergence of malignant ovarian granulosa cell tumor after a period of remission.


Refractory Ovarian Transitional Cell Carcinoma

Ovarian transitional cell carcinoma that is resistant to treatment.


Stage I Ovarian Cancer AJCC v6 and v7

Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Benign Ovarian Seromucinous Tumor

A non-metastasizing mixed epithelial neoplasm that arises from the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous. There is no evidence of atypia. This category includes seromucinous cystadenoma and seromucinous adenofibroma.


Stage I Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2

Tumor confined to ovaries (one or both). (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Ovarian Carcinoid Tumor

A well differentiated neuroendocrine neoplasm that arises from the ovary.  Histologically, it is classified as insular, trabecular, mucinous, or stromal carcinoid.  Clinical manifestations of carcinoid syndrome occur in approximately thirty percent of patients with insular carcinoid tumor.  Carcinoid syndrome is rare in other types of primary ovarian carcinoid tumor.  With the exception of mucinous carcinoid tumor, the prognosis is favorable.  Primary ovarian mucinous carcinoid tumor has a more aggressive clinical course and it can metastasize to other anatomic sites.


Ovarian cancer stage III

Stage III includes: T3, N0, M0.  T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Borderline Ovarian Endometrioid Adenofibroma

An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.


Stage IIA Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIA includes: T2a, N0, M0. T2a: Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


FIGO Stage IC1 Ovarian Cancer

Stage IC ovarian cancer with surgical spill. (FIGO, 2014)


ovarian primitive germ cell tumor

A malignant tumor that arises from the ovary and is characterized by the presence of malignant germ cell components but lacks a teratoma component.


Ovarian Cancer by FIGO Stage

A category of staging terms for ovarian cancer according to the International Federation of Gynecology and Obstetrics (FIGO), 2014. AJCC ovarian cancer stage terms from the 6th and 7th editions that are synonymous to the FIGO ovarian cancer staging classification of 2014 are included as preferred terms.


Metastatic Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma that has spread from its original site of growth to another anatomic site.


Platinum-Refractory Ovarian Carcinoma

Ovarian carcinoma that progresses during platinum therapy or within one month of completing the last platinum therapy.


liposarcoma of the ovary

A malignant adipose tissue neoplasm of the ovary.


Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor with Microinvasion

A low grade ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells. Microinvasion of the ovarian stroma is present.


Benign germ cell tumor of ovary

A germ cell tumor that arises from the ovary. There is no evidence of atypia or metastases. The vast majority of cases are benign dermoid cysts.


Ovarian Sertoli Cell Tumor

A rare, typically benign ovarian neoplasm composed of Sertoli cells. Patients may present with pseudoprecocity, menometrorrhagia, amenorrhea, hirsutism, and hoarseness.  Rarely it may invade the ovarian stroma and extend beyond the ovary.


FIGO Stage IIIC Ovarian Cancer

Ovarian cancer with macroscopic, extrapelvic, peritoneal metastasis greater than 2 cm +/- positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. (FIGO, 2014)


childhood choriocarcinoma of the ovary

A non-gestational choriocarcinoma that arises from the ovary and occurs in children.


Metastatic Ovarian Small Cell Carcinoma, Hypercalcemic Type

A primary small cell carcinoma of the ovary that is associated with hypercalcemia and has metastasized to other anatomic sites.


Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor

An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is often fibrotic. There is no evidence of stromal invasion.


Borderline Ovarian Serous Tumor/Atypical Proliferative Ovarian Serous Tumor with Microinvasion

A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic serous epithelial cells, atypia, and microinvasion of the ovarian stroma.


Ovarian Cellular Fibroma

A benign neoplasm arising from soft tissue of the ovary. It is characterized by the presence of spindle-shaped fibroblasts and increased cellularity.


Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor

A low grade, non-invasive ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells.


Benign Ovarian Serous Tumor

A non-metastasizing neoplasm that arises from the ovary and is characterized by the presence of neoplastic epithelium that resembles the epithelium of the fallopian tube. There is no evidence of atypia.  It includes serous cystadenoma, serous adenofibroma, serous cystadenofibroma, and surface papilloma.


Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor

A Sertoli-Leydig cell tumor of the ovary characterized by the presence of spindle-shaped gonadal stromal cells and Sertoli cells, some of which are atypical. Leydig cells are also present forming clusters at the periphery of the cellular aggregates. Metastases have been reported in a minority of patients.


Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor

The reemergence of borderline ovarian epithelial tumor after a period of remission.


Ovarian Adenomatoid Tumor

A rare benign mesothelial tumor that arises from the ovary. It is characterized by the presence of gland-like structures.


Ovarian Sex Cord-Stromal Tumor Associated with Peutz-Jeghers Syndrome

A sex cord-stromal tumor that arises from the ovary in a patient diagnosed with Peutz-Jeghers syndrome.


Stage III Ovarian Polyembryoma AJCC v6 and v7

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Juvenile Bilateral Ovarian Granulosa Cell Tumor

A juvenile granulosa cell tumor that involves both ovaries.


Refractory Ovarian Adenocarcinoma

Ovarian adenocarcinoma that is resistant to treatment.


Stage II Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2

Tumor involves one or both ovaries with pelvic extension (below the pelvic brim). (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Stage III Ovarian Dysgerminoma AJCC v6 and v7


Ovarian Fibromatosis and Massive Edema

A rare benign lesion characterized by tumor-like enlargement of the ovaries due to fibroblastic proliferation with collagen deposition (fibromatosis) or stromal accumulation of edema fluid (massive edema). It presents in premenopausal patients, with menstrual abnormalities, abdominal pain, or androgenic manifestations. Most cases are unilateral. (WHO 2020)


luteoma of pregnancy

A non-neoplastic and self-limited condition that occurs during pregnancy. It is characterized by proliferation of luteinized stromal cells that replace the normal ovarian stromal cells. It is usually manifested with bilateral multinodular ovarian masses. Treatment is not required.


Ovarian Sertoli-Leydig Cell Tumor with Heterologous Elements

A Sertoli-Leydig cell tumor that arises from the ovary. It is characterized by the presence of epithelial and/or mesenchymal components and neoplasms that arise from these components.


Microsatellite Stable Ovarian Carcinoma

Ovarian carcinoma characterized by the absence of microsatellite instability.


Ovarian Trabecular Carcinoid Tumor

A carcinoid tumor that arises from the ovary and is characterized by the presence of columnar cells with abundant cytoplasm forming ribbons.  The prognosis is excellent.


Childhood Ovarian Gynandroblastoma

An ovarian gynandroblastoma that occurs during childhood.


Mucinous adenofibroma of borderline malignancy

A low malignant potential adenofibroma of the ovary It is characterized by an atypical epithelial hyperplasia. The epithelial cells contain intracytoplasmic mucin. There is no evidence of stromal destructive invasion.


Stage IC Ovarian Cancer AJCC v6 and v7

Stage IC includes: T1c, N0, M0. T1c: Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Refractory Malignant Ovarian Brenner Tumor

Malignant ovarian Brenner tumor that is resistant to treatment.


Stage IIB Ovarian Cancer AJCC v6 and v7

Stage IIB includes: T2b N0, M0.  T2b: Extension and/or implants on other pelvic tissues.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


ovarian granulosa cell tumor

A granulosa-stromal cell tumor that arises from the ovary. It is characterized by the presence of granulosa cells that comprise at least ten percent of the cellular population. The granulosa cells are often found in a background that contains theca and fibrous cells. There are two major subtypes recognized, adult and juvenile granulosa cell tumor. Clinically, patients may present with an abdominal mass. Symptoms depend on the patient's age. The most important indicator of prognosis is tumor stage. Age over forty years at the time of the initial diagnosis, large tumor size, bilaterality, cellular atypia, and increased mitotic activity are factors indicating a potentially aggressive clinical course and relative poor prognosis.


Clear cell adenofibroma of borderline malignancy

An epithelial neoplasm with low malignant potential affecting the ovary. It is characterized by the presence of atypical glands and/or cystic spaces lined with clear or hobnail cells.


Stage IB Ovarian Cancer AJCC v6 and v7

Stage IB includes: T1b, N0, M0. T1b: Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Borderline Ovarian Serous Cystadenofibroma

A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of cystic spaces which are lined by atypical serous epithelial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.


Recurrent High Grade Ovarian Endometrioid Adenocarcinoma

The reemergence of high-grade ovarian endometrioid adenocarcinoma after a period of remission.


Hilus cell tumor

A benign Leydig cell tumor which arises in the hilar area of the ovary.


Benign Brenner Tumor

A benign neoplasm that arises from the ovary and is composed of nests of neoplastic urothelial-type cells in a fibrotic stroma. There is no evidence of atypia or invasion.


Platinum-Sensitive Ovarian Carcinoma

Ovarian carcinoma that has a documented response to platinum-based chemotherapy.


Unresectable Ovarian Carcinoma

Ovarian carcinoma that is not amenable to surgical resection.


Borderline Ovarian Clear Cell Cystadenofibroma

An epithelial neoplasm with low malignant potential affecting the ovary. It is characterized by the presence of prominent cystic spaces lined with atypical clear or hobnail cells. There is no evidence of stromal invasion.


Locally Recurrent Ovarian Carcinoma

The reemergence of ovarian carcinoma after a period of remission, at or adjacent to the site of the original tumor.


Recurrent Platinum-Sensitive Ovarian Carcinoma

The reemergence of platinum-sensitive ovarian carcinoma after a period of remission.


ovarian Wilms tumor

An embryonal neoplasm arising from the ovary with morphologic features resembling Wilms tumor of the kidney. It occurs during the reproductive age and may present as a rapidly growing adnexal mass.


Recurrent Ovarian Cystadenocarcinoma

The reemergence of ovarian cystadenocarcinoma after a period of remission.


Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Borderline Ovarian Serous Adenofibroma

A low malignant potential adenofibroma arising from the ovary. It is characterized by an atypical epithelial hyperplasia. The epithelial cells are of serous type. There is no evidence of stromal destructive invasion.


Childhood Ovarian Neoplasm

A neoplasm that affects the ovary during childhood.


Stage IA Ovarian Cancer AJCC v8

Stage IA includes: T1a, N0, M0. T1a: Ovarian cancer with tumor limited to one ovary (capsule intact); no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2 Stage, Tier 1

A term that refers to the staging of childhood ovarian germ cell tumor according to the tier 1 Toronto childhood cancer staging guidelines v2.


Childhood Malignant Ovarian Germ Cell Tumor

A malignant germ cell tumor in children arising from the ovary.  It includes the dysgerminoma, yolk sac tumor, choriocarcinoma, embryonal carcinoma and immature teratoma.


Borderline Ovarian Clear Cell Tumor

An epithelial neoplasm with low malignant potential affecting the ovary.  It is characterized by the presence of clear or hobnail cells.  In some cases, the cells may display nuclear atypia and prominent nucleoli.  When such cells are present, they remain confined to the glands.  There is no evidence of stromal invasion.


Congenital Ovarian Failure

Ovarian failure, the cause of which is present at birth.


Stage I Ovarian Cancer AJCC v8

Stage I includes: T1, N0, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Metastatic Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2

Distant metastatic disease excluding peritoneal metastases. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Stage IIIA Ovarian Cancer AJCC v8

Stage IIIA includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Ovarian Stromal Tumor with Minor Sex Cord Elements

A rare, benign sex cord-stromal tumor of the ovary characterized by the presence of a fibrothecomatous stroma and scattered sex cord elements. Although it is usually hormonally inactive, cases associated with endometrial hyperplasia or adenocarcinoma have been reported.


Sertoli-Leydig cell tumor, retiform

A Sertoli-Leydig cell tumor characterized by the presence of spaces that resemble rete testis (retiform elements).  These spaces form anastomosing patterns and comprise at least ten percent but less than ninety percent of the tumor.  When the retiform elements comprise ninety percent or more of the tumor, the term retiform Sertoli-Leydig cell tumor is used.  A minority of patients may have an aggressive clinical course.


Childhood Ovarian Nongerminomatous Germ Cell Tumor

A nongerminomatous germ cell tumor that arises in the ovary and occurs in children.


Regional Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2

Tumor involves one or both ovaries with pelvic extension and/or spread to the peritoneum outside the pelvis and/or retroperitoneal lymph nodes. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Ovarian Mixed Germ Cell-Sex Cord-Stromal Tumor

A neoplasm that arises from the ovary and is characterized by the presence of germ cell and sex cord-stromal tissues that are intimately admixed.  If there is no malignant germ cell component present, the clinical course is benign.


Metastatic Malignant Ovarian Germ Cell Tumor

A malignant germ cell tumor that arises from the ovary and has spread to another anatomic site.


Malignant Ovarian Steroid Cell Tumor

A steroid tumor of the ovary which has an aggressive clinical course and metastasizes to other anatomic sites. It is usually of large size and is characterized by nuclear atypia, increased mitotic activity, hemorrhage, and necrosis. Sometimes, patients have abdominal metastases at presentation.


Ovarian Insular Carcinoid Tumor

A carcinoid tumor that arises from the ovary and is characterized by the presence of round cells with abundant eosinophilic cytoplasm forming cribriform patterns.  Clinical manifestations of carcinoid syndrome occur in approximately thirty percent of patients.  The prognosis is favorable.


Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Ovarian Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified

An ovarian mixed germ cell-sex cord-stromal tumor in which the neoplastic cellular infiltrate does not have the distinctive appearance of a gonadoblastoma.


Unresectable Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma that is not amenable to surgical resection.


FIGO Grade 1 Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma exhibiting 5% or less solid non-glandular, non-squamous growth.


Recurrent ovarian cancer

The reemergence of ovarian carcinoma after a period of remission.


Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2 Stage, Tier 2

A term that refers to the staging of childhood ovarian germ cell tumor according to the tier 2 Toronto childhood cancer staging guidelines v2.


ovarian neuroendocrine neoplasm

An epithelial neoplasm with neuroendocrine differentiation that arises from the ovary. It includes carcinoid tumor, small cell carcinoma pulmonary type, and large cell neuroendocrine carcinoma.


Ovarian Leiomyoma

A benign smooth muscle neoplasm arising from the ovary. It is usually characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern. Variants with increased cellularity, increased mitotic activity, myxoid changes, or epithelioid morphology have also been reported.


ovarian benign neoplasm

A non-metastasizing neoplasm that arises from the ovary. Representative examples include serous cystadenoma, mucinous cystadenoma, clear cell adenofibroma, benign Brenner tumor, thecoma, and fibroma.


Refractory Ovarian Mucinous Adenocarcinoma

Ovarian mucinous adenocarcinoma that is resistant to treatment.


Stage IV Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2

Distant metastasis (excludes peritoneal metastases). (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Ovarian Signet Ring Cell Carcinoma

An extremely rare adenocarcinoma that arises from the ovary. It is characterized by the presence of signet ring malignant epithelial cells.


Ovarian Leydig Cell Tumor

An ovarian Leydig cell tumor for which the site of origin (ovarian hilus or ovarian stroma) cannot be determined.


Recurrent Ovarian Seromucinous Carcinoma

The reemergence of ovarian seromucinous carcinoma after a period of remission.


Stage IIC Ovarian Cancer AJCC v6 and v7

Stage IIC includes: T2c, N0, M0.  T2c: Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washing.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Recurrent Platinum-Resistant Ovarian Carcinoma

The reemergence of platinum-resistant ovarian carcinoma after a period of remission.


Recurrent Ovarian Germ Cell Tumor

The reemergence of ovarian germ cell tumor after a period of remission.


Stage IA Ovarian Cancer

Stage IA includes: T1a, N0, M0.  T1a: Tumor limited to one ovary; capsule intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor with Microinvasion

A low grade ovarian epithelial neoplasm characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. Microinvasion of the ovarian stroma is present.


Locally Advanced Platinum-Resistant Ovarian Carcinoma

Platinum-resistant ovarian carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Ovarian Cancer by AJCC v6 and v7 Stage

A category of staging terms for ovarian cancer according to the American Joint Committee on cancer (AJCC) 6th and 7th editions. International Federation of Gynecology and Obstetrics (FIGO) ovarian cancer staging terms prior to 2014 are included in this category if synonymous with the AJCC terms.


Stage II Ovarian Dysgerminoma AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Refractory Ovarian Undifferentiated Carcinoma

Ovarian undifferentiated carcinoma that is resistant to treatment.


Metastatic Ovarian Undifferentiated Carcinoma

Ovarian undifferentiated carcinoma that has spread from its original site of growth to another anatomic site.


Recurrent Ovarian Endometrioid Adenocarcinoma

The reemergence of ovarian endometrioid adenocarcinoma after a period of remission.


Stage IV Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Childhood Ovarian Sertoli-Leydig Cell Tumor

An ovarian Sertoli-Leydig cell tumor that occurs during childhood.


ovarian germ cell tumor

A neoplasm that arises from the ovary and originates from germ cells. Representative examples include teratoma, embryonal carcinoma, yolk sac tumor, and dysgerminoma.


Ovarian stromal hyperplasia

A non-neoplastic disorder that usually affects postmenopausal women.  It is characterized by proliferation of ovarian stromal cells without evidence of atypia.  There is usually bilateral ovarian involvement.  The ovaries may or may not be enlarged.


FIGO Stage IC2 Ovarian Cancer

Stage IC ovarian cancer with capsule rupture before surgery or tumor on ovarian surface. (FIGO, 2014)


ovary leiomyosarcoma

An aggressive malignant smooth muscle neoplasm, arising from the ovary. It is characterized by a proliferation of neoplastic spindle cells.


Lipid cell tumor of ovary

An ovarian tumor in which the vast majority of the cells (more than 90% of the tumor cells) resemble steroid hormone-secreting cells. It usually presents with androgenic manifestations. Approximately one-third of the cases follow a malignant clinical course.


Metastatic Microsatellite Stable Ovarian Carcinoma

Microsatellite stable ovarian carcinoma that has spread from its original site of growth to another anatomic site.


Borderline Ovarian Endometrioid Tumor

A rare, low grade ovarian epithelial neoplasm characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells.


FIGO Stage IC3 Ovarian Cancer

Stage IC ovarian cancer with malignant cells in the ascites or peritoneal washings. (FIGO, 2014)


Stage IV Ovarian Dysgerminoma AJCC v6 and v7


Stage IC Ovarian Cancer AJCC v8

Stage IC includes: T1c, N0, M0. T1c: Ovarian cancer with tumor limited to one or both ovaries, with any of the following: surgical spill, capsule ruptured before surgery or tumor on ovarian surface, or malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Ovarian Sclerosing Stromal Tumor

A benign ovarian stromal tumor characterized by the presence of cellular areas which contain fibroblasts and round cells. The cellular areas are separated by sclerotic or edematous hypocellular tissue. Symptoms include abdominal discomfort and menstrual abnormalities.


Stage IA Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IA includes: (T1a, N0, M0). T1a: Tumor limited to one ovary; capsule intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Metastatic Platinum-Resistant Ovarian Carcinoma

Platinum-resistant ovarian carcinoma that has spread from its original site of growth to another anatomic site.


FIGO Stage IVB Ovarian Cancer

Ovarian cancer with hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity). (FIGO, 2014)


Benign Ovarian Clear Cell Tumor

A non-metastasizing neoplasm that arises from the ovary. It is characterized by a predominance of clear and hobnail benign epithelial cells.


Recurrent Ovarian Clear Cell Adenocarcinoma

The reemergence of ovarian clear cell adenocarcinoma after a period of remission.


Metastatic Ovarian Mucinous Adenocarcinoma

Ovarian mucinous adenocarcinoma that has spread from its original site of growth to another anatomic site.


Ovarian Steroid Cell Tumor, Not Otherwise Specified

A steroid cell tumor that arises from the ovary and is defined by morphologic features that do not fit into the categories of Leydig cell tumor and stromal luteoma.  These features include solid proliferations of polygonal neoplastic cells with eosinophilic and granular cytoplasm.  Grossly, these tumors usually present as large and well circumscribed masses and are usually associated with androgenic manifestations.  Approximately one third of the cases have a malignant clinical course.


Stage IB Ovarian Cancer AJCC v8

Stage IB includes: T1b, N0, M0. T1b: Ovarian cancer with tumor limited to one or both ovaries (capsules intact); no tumor on ovarian surface; no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Refractory Ovarian Carcinoma

Ovarian carcinoma that is resistant to treatment.


Stage I Ovarian Polyembryoma AJCC v6 and v7

Stage I includes: (T1, N0, M0). T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Ovarian Granulosa-Stromal Cell Tumor

A group of sex cord-stromal tumors that arise from the ovary.  These tumors are characterized by the presence of granulosa cells, stromal cells, and/or theca cells.  This group includes granulosa cell tumor and tumors of the thecoma/fibroma group.


ovarian melanoma

A melanoma (disease) that involves the ovary.


Refractory Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma that is resistant to treatment.


Ovarian Neuroectodermal-Type Tumor

A rare ovarian malignant tumor with neuroectodermal differentiation. It is characterized either by a small round cell proliferation or by neuronal or glial differentiation.


Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements

An ovarian Sertoli-Leydig cell tumor of intermediate differentiation, characterized by the presence of a heterologous component, usually consisting of cartilage, skeletal muscle, or rhabdomyosarcoma.


Childhood Benign Ovarian Neoplasm

A childhood neoplasm that arises from the ovary and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


Ovarian epithelial cancer stage II

Stage II includes: T2, N0, M0.  T2: Tumor involves one or both ovaries with pelvic extension and/or implants.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Localized Childhood Ovarian Germ Cell Tumor by Toronto Guidelines v2

Tumor confined to ovaries. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


malignant germ cell tumor of ovary

Malignant germ cell tumor of ovary is a rare ovarian cancer arising from germ cells in the ovary, frequently unilateral at diagnosis which characteristically presents during adolescence with pelvic mass, fever, vaginal bleeding and acute abdomen.


Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma

A non-invasive serous neoplasm that arises from the ovary and shows micropapillary and/or cribriform architectural patterns.  It is composed of round epithelial cells with scant cytoplasm and moderate nuclear atypia.


Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements

An ovarian poorly differentiated Sertoli-Leydig cell tumor. It is characterized by the presence of a heterologous component, usually consisting of cartilage, skeletal muscle, or rhabdomyosarcoma.


High Grade Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma exhibiting more than 50% solid non-glandular, non-squamous growth.


Well Differentiated Ovarian Sertoli-Leydig Cell Tumor

A Sertoli-Leydig tumor of the ovary characterized by the presence of Sertoli cells in tubules without evidence of significant nuclear atypia or mitotic activity. Primitive gonadal stromal cells are not present. It usually follows a benign clinical course.


ovarian endometrioid adenofibroma

A benign neoplasm of the ovary characterized by the presence of glandular structures with endometrial-type well-differentiated cells in a fibrotic stroma.


Stage IIIA2 Ovarian Cancer AJCC v8

Stage IIIA2 includes: T3a, N0/N1, M0. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7

Stage I includes: (T1, N0, M0). T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Ovarian Retiform Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements

A retiform Sertoli-Leydig cell tumor that arises from the ovary. It is characterized by the presence of an epithelial and/or mesenchymal heterologous component.


undifferentiated sarcoma of ovary

An aggressive high grade sarcoma that arises from the ovary.  It is characterized by the presence of marked pleomorphism and nuclear atypia in the neoplastic mesenchymal cells.  The prognosis is poor.


Stage IIIA1 Ovarian Cancer AJCC v8

Stage IIIA1 includes: T1/2, N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Stage IIC Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIC includes: T2c, N0, M0. T2c: Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washing. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Ovarian Leydig Cell Tumor, Non-Hilar Type

A Leydig cell tumor that arises from the ovarian stroma.


Benign thecoma

A thecoma of the ovary that does not metastasize to other anatomic sites.


Borderline Ovarian Mucinous Tumor, Intestinal Type

A neoplasm of low malignant potential arising from the ovary.  It is characterized by the proliferation of neoplastic mucinous epithelial cells that resemble intestinal epithelial cells.  There is no evidence of stromal invasion.


ovarian sarcoma

A rare, aggressive malignant mesenchymal neoplasm that arises from the ovary. The prognosis is poor.


FIGO Stage III Ovarian Cancer

Ovarian cancer involving 1 or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes. (FIGO, 2014)


Ovarian Sertoli-Leydig Cell Tumor Molecular Subtypes

A term that refers to the classification of ovarian Sertoli-Leydig cell tumors according to their molecular characteristics.


FIGO Stage II Ovarian Cancer

Ovarian cancer involving one or both ovaries with pelvic extension (below the pelvic brim) or primary peritoneal cancer. (FIGO, 2014)


Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7


Advanced Ovarian Carcinosarcoma

Ovarian carcinosarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Recurrent Extrarenal Rhabdoid Tumor of the Ovary

The reemergence of extrarenal rhabdoid tumor of the ovary after a period of remission.


Extrarenal Rhabdoid Tumor of the Ovary

An extrarenal rhabdoid tumor affecting the ovary.


Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


adenocarcinofibroma

A carcinoma arising from the ovary. It is characterized by the presence of malignant epithelial cells in a fibrotic stroma. Histologic variants include clear cell, serous, mucinous, and endometrioid adenocarcinofibroma.


Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor

Stage III includes: T3, N0, M0.  T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Adult Type Ovarian Granulosa Cell Tumor

A low-grade malignant sex cord-stromal tumor that occurs in the ovary and affects middle aged to post-menopausal women. It is composed of granulosa cells in an often fibrothecomatous stroma. The neoplastic cells may form various patterns including the microfollicular, which is characterized by the presence of Call-Exner bodies, macrofollicular, insular, trabecular, and diffuse pattern. Signs and symptoms include abdominal mass, hemoperitoneum, and ascites. Estrogenic and rarely androgenic manifestations may be present. The vast majority of cases present as stage I tumors; however, all tumors have a potential for aggressive clinical course.


Stage II Ovarian Germ Cell Tumor AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Recurrent Ovarian Mucinous Adenocarcinoma

The reemergence of ovarian mucinous adenocarcinoma after a period of remission.


Acquired Ovarian Failure

Ovarian failure, the cause of which is not present at birth.


serous adenocarcinofibroma of ovary

A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells of serous type, forming glandular, papillary, and solid patterns.


Stage IV Ovarian Carcinoma

A carcinoma that arises from the ovary and has metastasized to another anatomic site.


Ovarian Non-Neoplastic Disorder

A non-neoplastic disorder that affects the ovary.  Representative examples include endometriosis and polycystic ovarian disease.


Borderline Ovarian Mucinous Tumor, Endocervical-Like

A neoplasm of low malignant potential arising from the ovary.  It is characterized by the proliferation of neoplastic epithelial cells that resemble endocervical epithelial cells.  There is no evidence of stromal invasion.


Gonadotropin-Resistant Ovary Syndrome

Ovarian dysfunction due to a defect at the receptor or post receptor level, or due to the presence of antibodies against gonadotropin receptors, resulting in deficient gonadotropin signaling that causes elevated concentrations of follicle stimulating hormone and/or luteinizing hormone. A distinguishing feature is the presence of normal numbers of ova.


Borderline Ovarian Seromucinous Tumor

A low grade ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells.


BRCA-Associated Ovarian Carcinoma

Ovarian carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


Solid Pseudopapillary Neoplasm of the Ovary

An exceedingly rare solid pseudopapillary neoplasm that occurs in ectopic pancreatic tissue in the ovary.


Thecoma, luteinized

A variant of ovarian thecoma characterized by the presence of lutein cells. It is associated with a lower frequency of estrogenic manifestations compared to typical thecomas. In a minority of cases androgenic manifestations are present.


Low Grade Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma exhibiting 50% or less solid non-glandular, non-squamous growth.


Ovarian Tumor of the Thecoma/Fibroma Group

A group of neoplasms that arise from the ovary and represent a spectrum of tumors ranging from neoplasms that are composed entirely of fibroblasts to those that are composed predominantly of theca cells.


Ovarian Luteinized Thecoma Associated with Sclerosing Peritonitis

A rare usually bilateral luteinized thecoma that arises from the ovary and is associated with sclerosing peritonitis. It occurs mostly in premenopausal women. The ovarian tumor is benign but patients may develop intestinal obstruction due to the sclerosing peritonitis.


Ovarian germ cell choriocarcinoma stage III

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIA Ovarian Cancer AJCC v8

Stage IIA includes: T2a, N0, M0. T2a: Ovarian cancer with tumor extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Unresectable Ovarian Undifferentiated Carcinoma

Ovarian undifferentiated carcinoma that is not amenable to surgical resection.


FIGO Stage IIIA1 Ovarian Cancer

Ovarian cancer with positive retroperitoneal lymph nodes only. (FIGO, 2014)


Platinum-Resistant Ovarian Carcinoma

Ovarian carcinoma that progresses between one and six months of completing the last platinum therapy.


FIGO Stage IIIA Ovarian Cancer

Ovarian cancer with positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis. (FIGO, 2014)


Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7


FIGO Stage IIIA1(ii) Ovarian Cancer

Ovarian cancer with positive retroperitoneal lymph nodes only. Metastasis greater than 10 mm. (FIGO, 2014)


Refractory Ovarian Seromucinous Carcinoma

Ovarian seromucinous carcinoma that is resistant to treatment.


ovarian sertoli-stromal cell tumor

A sex cord-stromal tumor that arises from the ovary and is composed entirely of, or in various combinations of, Sertoli cells, Leydig cells, and fibroblast-like cells.


Stage II Ovarian Cancer AJCC v8

Stage II includes: T2, N0, M0. T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Benign Ovarian Luteinized Thecoma

A non-metastasizing thecoma of the ovary that is characterized by the presence of lutein cells.


ovarian malignant mesothelioma

A rare malignant mesothelial neoplasm that usually involves both the ovarian surface and the ovarian stroma. In most cases there is bilateral ovarian involvement.


Childhood Ovarian Sclerosing Stromal Tumor

A sclerosing stromal tumor that arises from the ovary during childhood.


Ovarian Seromucinous Adenofibroma

A non-metastasizing mixed epithelial neoplasm that arises from the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous and prominent fibrous stroma..


benign endometrioid tumor of ovary

A non-metastasizing neoplasm that arises from the ovary and is characterized by the presence of glands or cysts lined by benign endometrial-type cells. It includes endometrioid adenofibroma, endometrioid cystadenofibroma, and endometrioid cystadenoma.


Stage IIIC Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal metastasis beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Proliferating Brenner Tumor

A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of neoplastic atypical urothelial-type cells in a fibrotic stroma without evidence of invasion.


Typical Ovarian Thecoma

An ovarian thecoma characterized by the presence of cells with uniform nuclei and abundant vacuolated cytoplasm.  Mitoses are not present or, when present, are rare.


Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor with Intraepithelial Carcinoma

A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic mucinous epithelial cells, atypia, and the presence of intraepithelial carcinoma.


Unresectable Ovarian Mucinous Adenocarcinoma

Ovarian mucinous adenocarcinoma that is not amenable to surgical resection.


choriocarcinoma of ovary

A choriocarcinoma arising from the ovary. When it appears before puberty is of germ cell origin. In children and young adults signs and symptoms include precocious pseudopuberty and vaginal bleeding. Serum human chorionic gonadotropin is elevated. Germ cell derived ovarian choriocarcinoma should be differentiated from primary or metastatic gestational choriocarcinoma affecting the ovary. The prognosis of germ cell derived choriocarcinoma is less favorable and requires more aggressive chemotherapy treatment regimens compared to gestational choriocarcinoma.


Ovarian Dedifferentiated Carcinoma

An aggressive carcinoma arising from the ovary.  Most patients present with advanced disease.  Microscopically, it is characterized by the presence of an undifferentiated carcinomatous component and a second component of either endometrioid carcinoma or, rarely, serous carcinoma.


Borderline Ovarian Endometrioid Cystadenofibroma

An epithelial neoplasm that arises from the ovary characterized by the presence of cystic spaces which are lined by atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.


Ovarian Sex Cord Tumor with Annular Tubules

An ovarian sex cord-stromal tumor characterized by the presence of Sertoli cells forming annular tubules. It may be associated with Peutz-Jeghers syndrome. Cases associated with Peutz-Jeghers syndrome have followed a benign clinical course. Cases which are not associated with Peutz-Jeghers syndrome have been reported having a clinically malignant course.


Stage III Ovarian Germ Cell Tumor AJCC v6 and v7

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage III Ovarian Cancer AJCC v8

Stage III includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0; IIIB: T3b, N0/N1, M0; IIIC: T3c, N0/N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. T3b: Ovarian cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. T3c: Ovarian cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Ovarian Retiform Sertoli-Leydig Cell Tumor

A Sertoli-Leydig cell tumor of the ovary in which anastomosing, slit-like spaces resembling rete testis constitute at least 90% of the tumor elements. It may present with estrogenic and less often androgenic manifestations. It usually follows a benign clinical course.


Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor

A non-invasive neoplasm that arises from the ovary and is composed of gastrointestinal-type, mucin-containing epithelial cells.  It shows greater cellular proliferation and cytologic atypia as compared to benign ovarian mucinous tumors.


Unresectable Platinum-Resistant Ovarian Carcinoma

Platinum-resistant ovarian carcinoma that is not amenable to surgical resection.


Ovarian germ cell choriocarcinoma stage IV

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Borderline Ovarian Clear Cell Tumor/Atypical Proliferative Ovarian Clear Cell Tumor

A non-invasive clear cell adenofibromatous neoplasm that arises from the ovary. It is characterized by the presence of atypia in the glandular epithelium.


Stage IIIA Choroidal and Ciliary Body Melanoma AJCC v8

Stage IIIA includes: (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0). T2c: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T2d: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T3b: Tumor size category 3 with ciliary body involvement. T3c: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4a: Tumor size category 4 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)


tRNA pseudouridine(55) synthase activity

Catalysis of the reaction: uridine(55) in tRNA = pseudouridine(55) in tRNA.


isochorismate synthase activity

Catalysis of the reaction: chorismate = isochorismate.


hydroperoxy icosatetraenoate isomerase activity

A hydroperoxy icosatetraenoate = a hydroxy epoxy icosatrienoate.


23S rRNA pseudouridine(955/2504/2580) synthase activity

Catalysis of the reaction: uridine(955/2504/2580) in 23S rRNA = pseudouridine(955/2504/2580) in 23S rRNA.


5-(carboxyamino)imidazole ribonucleotide mutase activity

Catalysis of the reaction: 5-carboxyamino-1-(5-phospho-D-ribosyl)imidazole = 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate.


UDP-arabinopyranose mutase activity

Catalysis of the reaction: UDP-beta-L-arabinofuranose = UDP-beta-L-arabinopyranose.


Catalysis of the reaction: 2-(5'-methylthio)pentylmalate = 3-(5'-methylthio)pentylmalate.


methylaspartate mutase activity

Catalysis of the reaction: threo-3-methyl-L-aspartate = L-glutamate.


Catalysis of the reaction: glucose-1-phosphate = glucose-6-phosphate; using D-glucose as a cofactor.


Catalysis of the reaction: N-acetyl-alpha-D-glucosamine 1-phosphate = N-acetyl-D-glucosamine 6-phosphate.


squalene-hopene cyclase activity

Catalysis of the reaction: squalene = hop-22(29)-ene.


lysine 2,3-aminomutase activity

Catalysis of the reaction: L-lysine = (3S)-3,6-diaminohexanoate.


23S rRNA pseudouridine(2604) synthase activity

Catalysis of the reaction: uridine(2604) in 23S rRNA = pseudouridine(2604) in 23S rRNA.


rRNA pseudouridine synthase activity

Catalysis of the reaction: a uridine in rRNA = a pseudouridine in rRNA. Conversion of uridine in an rRNA molecule to pseudouridine by rotation of the C1'-N-1 glycosidic bond of uridine in RNA to a C1'-C5.


isomaltulose synthase activity

Catalysis of the reaction: sucrose = 6-O-alpha-D-glucopyranosyl-D-fructofuranose.


mitochondrial tRNA pseudouridine(27/28) synthase activity

Catalysis of the reaction: uridine(27/28) in mitochondrial tRNA = pseudouridine(27/28) in mitochondrial tRNA.


tRNA pseudouridine(32) synthase activity

Catalysis of the reaction: uridine(32) in tRNA = pseudouridine(32) in tRNA.


D-sedoheptulose 7-phosphate isomerase activity

Catalysis of the reaction: D-sedoheptulose-7-phosphate = D-alpha,beta-D-heptose 7-phosphate.


lanosterol synthase activity

Catalysis of the reaction: (S)-2,3-epoxysqualene = lanosterol. This is a cyclization reaction that forms the sterol nucleus.


Catalysis of the reaction: 2-(3-methylthiopropyl)malate(2-) = 3-(3'-methylthio)propylmalate.


arabidiol synthase activity

Catalysis of the reaction: oxidosqualene + H2O = arabidiol ((13R,14R,17E)-malabarica-17,21-diene-3beta,14-diol).


chorismate mutase activity

Catalysis of the reaction: chorismate = prephenate.


23S rRNA pseudouridine(1911/1915/1917) synthase activity

Catalysis of the reaction: uridine(1911/1915/1917) in 23S rRNA = pseudouridine(1911/1915/1917) in 23S rRNA.


3-(hydroxyamino)phenol mutase activity

Catalysis of the reaction: 3-hydroxyaminophenol = aminohydroquinone.


cycloartenol synthase activity

Catalysis of the reaction: (S)-2,3-epoxysqualene = cycloartenol.


thalianol synthase activity

Catalysis of the cyclization of 3(S)-oxidosqualene to (3S,13S,14R)-malabarica-8,17,21-trien-3-ol (thalianol).


pivalyl-CoA mutase activity

Catalysis of the reaction: pivalyl-CoA = 3-methylbutyryl-CoA.


cucurbitadienol synthase activity

Catalysis of the reaction: oxidosqualene = cucurbitadienol.


16S rRNA pseudouridine(516) synthase activity

Catalysis of the reaction: uridine(516) in 16S rRNA = pseudouridine(516) in 16S rRNA.


beta-amyrin synthase activity

Catalysis of the reaction: (S)-2,3-epoxysqualene = beta-amyrin. This reaction is the cyclization and rearrangement of (S)-2,3-epoxysqualene (2,3-oxidosqualene) into beta-amyrin.


tRNA pseudouridine(13) synthase activity

Catalysis of the reaction: uridine(13) in tRNA = pseudouridine(13) in tRNA.


(hydroxyamino)benzene mutase activity

Catalysis of the reaction: (hydroxyamino)benzene = 2-aminophenol.


tRNA pseudouridine(38/39) synthase activity

Catalysis of the reaction: uridine(38/39) in tRNA = pseudouridine(38/39) in tRNA.


o-hydroxylaminobenzoate mutase activity

Catalysis of the reaction: o-hydroxylaminobenzoate = 3-hydroxyanthranilate.


23S rRNA pseudouridine(746) synthase activity

Catalysis of the reaction: uridine(746) in 23S rRNA = pseudouridine(746) in 23S rRNA.